SOURCE: Medistem Inc.

Medistem Inc.

July 06, 2010 23:09 ET

Medistem Panama Founder Granted US Patent on Cancer Treatment Based on Patient's Own Cells

SAN DIEGO, CA--(Marketwire - July 6, 2010) -  Medistem Inc. (PINKSHEETS: MEDS). Medistem Panama, licensee of Medistem Inc., announced today issuance of US patent # 7,749,495 covering a new method for treating cancer that does not require use of chemotherapy or radiation. The procedure, which involves taking out patient cells, manipulating them, and re-introducing them into the body, has demonstrated positive results in patients with metastatic renal cell carcinoma, neuroblastoma, adenocarcinoma, breast cancer, sarcoma, and rectal cancer.

"Dr. Riordan has established cancer treatment centers using dendritic cell therapy over a decade ago, yet only this year did the FDA approve this approach," stated Thomas Ichim, CEO of Medistem Inc. "The groundbreaking findings that were granted the current patent attest to the successful integration of basic research and clinical practice that has been pioneered by the founder of Medistem Panama."

Medistem Panama is a biotechnology company located in Panama City, Panama which possesses stem cell isolation, manipulation, expansion, and storage capabilities. As a licensee of the American company, Medistem Inc., it is involved in basic research and applications of cord blood, placental matrix, bone marrow, and adipose derived stem cells. Medistem Panama routinely collaborates with scientists at leading North American Universities including University of California San Diego and University of Western Ontario.

"I am thankful to the clinical and basic research teams that have believed in and supported our dream of using the body's own cells to heal itself," stated Dr. Riordan. "Our current work at Medistem Panama with adult stem cells is a continuation of our dendritic cell work; the only difference is that instead of using the body's cells to fight cancer we are using the body's cells to fight degenerative diseases."

An example of Medistem's clinical successes can be seen in peer-reviewed publications describing adult stem cells for treatment of multiple sclerosis (freely available at http://www.translational-medicine.com/content/pdf/1479-5876-7-29.pdf) and heart failure (freely available at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf). Videos of patients treated with Medistem technologies can be seen on the Youtube channel www.youtube.com/cellmedicine.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:

    Thomas E Ichim
    Chief Executive Officer
    Medistem Inc.
    9255 Towne Centre Drive
    Suite 450
    San Diego CA 92122
    858 349 3617
    858 642 0027
    www.medisteminc.com

Webosphere

Keyword Cloud

View Website